Company Overview
Company Type: Private Company
Website: www.pacylex.com
Number of Employees: -
Year Founded: 2012
Total Amount Raised (CAD mm)†: 13.36
Total Rounds of Funding**:2
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
Pacylex Pharmaceuticals, Inc. develops medicines for hematologic and solid cancers. The company offers various medications that targets hematologic cancers. Pacylex Pharmaceuticals, Inc. was founded in 2012 and is based in Edmonton, Canada.


Financial Information (Currency: CAD, in mm)
Total Revenue
-
Operating Income
-
Total Assets
-
Gross Profit
-
EBITDA
-
Total Debt
-
Net Income
-
Estimated Number of Employees
-
Net Debt
-
* Hover over data point numbers for date and source.

Key Professionals
Name
Title
Weickert, Michael J.
CEO & Director
Libonati, Michele 
Chief Operating Officer
Berthiaume, Luc G.
CSO & Director
Mackey, John 
CMO & Director
Beauchamp, Erwan 
Director of Discovery Biology & Director

Key Board Members
Name
Title
Jacobs, Cindy 
Chairman
Weickert, Michael J.
CEO & Director
Berthiaume, Luc G.
CSO & Director
Mackey, John 
CMO & Director
Beauchamp, Erwan 
Director of Discovery Biology & Director
Borthakur, Gautam 
Member of Scientific Advisory Board
Craddock, Charles 
Member of Scientific Advisory Board
Gill, Ajit S.
Director
Huson, Mark 
Director
Masterson, Nola Elizabeth
Director
Pemmaraju, Naveen 
Member of Scientific Advisory Board


Primary Industry Classification
Pharmaceuticals


Primary Office Location
10230 Jasper Avenue Suite 4000 | Edmonton, AB | T5J 4P6 | Canada
Phone: 780 264 4295   

Current and Pending Investors
Investor
Initial Investment Date
Stake Type
Current Stake Amount
Round(s)
Greenfire Bio LLC
May-28-2021
Minority
-
Series A


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
May-28-2021
Jun-02-2021
Private Placement
Target
Pacylex Pharmaceuticals, Inc.
Greenfire Bio LLC

7.18
Mar-04-2020
Mar-04-2020
Private Placement
Target
Pacylex Pharmaceuticals, Inc.


3.90
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Jan-09-2023
Company Conference Presentations
Pacylex Pharmaceuticals, Inc. Presents at Biotech Showcase 2023, Jan-09-2023
Jun-28-2022
Company Conference Presentations
Pacylex Pharmaceuticals, Inc. Presents at MedInvest Oncology Investor Conference, Jun-28-2022 11:40 AM
Jun-02-2021
Private Placements
Pacylex Pharmaceuticals, Inc. announced that it has received CAD 8.658539 million in funding from Greenfire Bio LLC
May-28-2021
Private Placements
Pacylex Pharmaceuticals, Inc. announced that it expects to receive funding
Mar-04-2020
Private Placements
Pacylex Pharmaceuticals, Inc announced that it has received $3.9 million in funding


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
GlobalData

Sep 14, 2023 09:23 PM
Pacylex Pharmaceuticals, Inc.
Pacylex Pharmaceuticals Inc
Reports
49
GlobalData

Jun 19, 2023 05:37 AM
Pacylex Pharmaceuticals, Inc.
Pacylex Pharmaceuticals Inc
Reports
49
GlobalData

Mar 15, 2023 03:06 AM
Pacylex Pharmaceuticals, Inc.
Pacylex Pharmaceuticals Inc
Reports
47
GlobalData

Dec 15, 2022 10:24 PM
Pacylex Pharmaceuticals, Inc.
Pacylex Pharmaceuticals Inc
Reports
44
GlobalData

Sep 20, 2022 08:07 AM
Pacylex Pharmaceuticals, Inc.
Pacylex Pharmaceuticals Inc
Reports
43
Infinata, Inc.
Infinata Research
Jul 14, 2020 06:22 AM
Pacylex Pharmaceuticals, Inc.
Pacylex Pharmaceuticals, Inc - Company Report
Reports
8
Infinata, Inc.
Infinata Research
Jun 23, 2020 06:06 AM
Pacylex Pharmaceuticals, Inc.
Pacylex Pharmaceuticals, Inc - Company Report
Reports
8
Infinata, Inc.
Infinata Research
Mar 19, 2020 06:32 AM
Pacylex Pharmaceuticals, Inc.
Pacylex Pharmaceuticals, Inc - Company Report
Reports
8
Infinata, Inc.
Infinata Research
Dec 23, 2019 04:38 AM
Pacylex Pharmaceuticals, Inc.
Pacylex Pharmaceuticals, Inc - Company Report
Reports
8
Infinata, Inc.
Infinata Research
Sep 30, 2019 05:46 AM
Pacylex Pharmaceuticals, Inc.
Pacylex Pharmaceuticals, Inc - Company Report
Reports
8


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.


Upcoming Events
Date/Time
Type
Oct-17-2023
Conferences
Oct-17-2023 10:15 AM (PST)
Company Conference Presentations
* Future Events are subject to change.

Key Board Members Details
Name
Title
Phone
Fax
Email
Jacobs, Cindy 
Chairman
780 264 4295
-

Weickert, Michael J.
CEO & Director
780 264 4295
-
mweickert@seamedical.com
Berthiaume, Luc G.
CSO & Director
780 264 4295
-

Mackey, John 
CMO & Director
780 264 4295
-

Beauchamp, Erwan 
Director of Discovery Biology & Director
780 264 4295
-

Borthakur, Gautam 
Member of Scientific Advisory Board
780 264 4295
-

Craddock, Charles 
Member of Scientific Advisory Board
780 264 4295
-

Gill, Ajit S.
Director
780 264 4295
-

Huson, Mark 
Director
780 264 4295
-

Masterson, Nola Elizabeth
Director
(415) 725-4072
-
masterson@sciencefuturesinc.com
Pemmaraju, Naveen 
Member of Scientific Advisory Board
780 264 4295
-

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Weickert, Michael J.
CEO & Director
780 264 4295
-
mweickert@seamedical.com
Libonati, Michele 
Chief Operating Officer
780 264 4295
-

Berthiaume, Luc G.
CSO & Director
780 264 4295
-

Mackey, John 
CMO & Director
780 264 4295
-

Beauchamp, Erwan 
Director of Discovery Biology & Director
780 264 4295
-

* denotes that the relationship is proprietary

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
